Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Lola Oni, OBELola Oni is a specialist nurse consultan...
-
William Owen, MDDr. William Owen is a pediatric hematolo...
-
How This Disease Changes the Shape of Your Cells – Amber M. Yateshttps://www.youtube.com/watch?v=hRnrIpUM...
-
The Sickle Cell Care Coordination InitiativeThe Sickle Cell Care Coordination Initia...
-
Sickle Cell Disease Association of America, Inc.SCDAA provides leadership on a national ...
-
Translating sickle cell guidelines into practice for primary care providers with Project ECHOBackground: Approximately 100,000 perso...
-
Today’s Faces of Sickle Cell Disease: Tosin OlaDuring a long hospitalization in 2005, T...
